News & Events

News


Friday June 09, 2017

Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

Live Audio Webcast Will be on June 15, 2017 SAN DIEGO, June 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA. The live presentation takes place on Thursday, June 15 at 9:20am PT (12:20pm ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on ...


Friday June 02, 2017

Neurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders

SAN DIEGO, June 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the upcoming presentation of three posters at the 21st International Congress of Parkinson's Disease and Movement Disorders (MDS), including data from the KINECT 3 Phase III extension study of INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). The 21st International Congress of Parkinson's Disease and Movement Disorders will take place in Vancouver BC, Canada from June 4-8, 2017. Neurocrine's three posters will be presented on Tuesday, June 6, 2017 from 13:45 - 15:15 PDT: 399: Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dys...


Thursday June 01, 2017

Neurocrine Biosciences to Present at the Jefferies 2017 Global Healthcare Conference

Live Audio Webcast Will be on June 8, 2017 SAN DIEGO, June 1, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Jefferies 2017 Global Healthcare Conference in New York City. The live presentation takes place on Thursday, June 8 at 1:30pm ET (10:30am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximate...


Tuesday May 23, 2017

Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome

Study Provides Clear Path Forward for Future Pivotal Studies Company to Host Conference Call and Webcast Tuesday, May 23rd at 5:00 P.M. ET / 2:00 P.M. PT SAN DIEGO, May 23, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the initial Phase II Tourette syndrome T-Force GREEN study of INGREZZA®(valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint. The pre-specified primary endpoint was the change-from-baseline between the placebo and active groups in the Yale Global Tic Severity Scale (YGTSS) at Week 6 in the intent-to-treat (ITT) population. Exposure-response analysis showed that the selected doses for this placebo-cont...


Thursday May 18, 2017

Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting

SAN DIEGO, May 18, 2017 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX) announced today the upcoming presentation at the American Psychiatric Association (APA) Annual Meeting of pharmacokinetic data, as well as long-term data from the KINECT 3 Phase III extension study of INGREZZA® (valbenazine) capsules for the treatment of adults with TD. "This year's annual meeting of the APA is an excellent opportunity to present additional data and analyses from the extensive clinical development program both supporting and differentiating INGREZZA," said Chris O'Brien, M.D., Chief Medical Officer of Neurocrine. "We are particularly pleased to share this information with Psychiatrists who...

Events